Design, Development, and Optimization of Dexibuprofen Microemulsion Based Transdermal Reservoir Patches for Controlled Drug Delivery

Ali, Firdous Imran; Shoaib, Mohammad; Yousuf, Rabia Ismail; Ali, Syed Abid; Imtiaz, Muhammad; Bashir, Lubna; Naz, Shazia

doi:10.1155/2017/4654958

Cited by 20 publications

(11 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All the formulations best comply with Makoid-Banakar model showing R 2 values in the range of 0.998-0.999 as shown in Table 3. The reservoir patches of estradiol [22] and dexibuprofen [41]. have also followed the Makoid-Banakar model.…”

Section: In Vitro Release Studymentioning

confidence: 99%

“…Thacharodi et al also concluded that the surface area of device affect the drug release and decrease in the area has also reduced the release of drug from the device [53] Fig 4(C) represents drug permeation from LRX patches with different surface area and was found approximately similar i.e 115.58 μg/cm 2 /h, 110 μg/cm 2 /h and 126.51 μg/cm 2 /h, respectively Similar findings were reported by Ali et al, where a change in the surface area resulted in a different release profile but approximately similar permeation profile. [41].…”

Section: Effect Of Gelling Agent Concentrationmentioning

confidence: 99%

See 1 more Smart Citation

Lornoxicam controlled release transdermal gel patch: Design, characterization and optimization using co-solvents as penetration enhancers

et al. 2020

Self Cite

View full text Add to dashboard Cite

The aim of the current study was to develop membrane-based transdermal patches of lornoxicam gel using oleic acid (OA)and propylene glycol (PG) as penetration enhancers to improve drug delivery across the skin and to evaluate in vivo analgesic and anti-inflammatory activity. For this purpose, nine formulations were developed in accordance with 3 2 factorial design using Design Expert ® 11. The concentration of propylene glycol (X 1) and oleic acid (X 2) were selected as independent variable whereas Q 10 (Y 1), flux (Y 2) and lag time (Y 3) were considered as the response variables. The impact of drug loading, surface area, gel concentration, membrane variation and agitation speed on drug release and permeation was also studied. The skin sensitivity reaction, analgesic activity and anti-inflammatory action of the optimized patch were also determined in Albino Wistar rats. Stability studies were performed for three months at three different temperature conditions. The result suggests that a membrane-based system with controlled zero-order drug release of 95.8 ± 1.121% for 10 h exhibiting flux of 126.51±1.19 μg/cm 2 /h and lag time of 0.908 ±0.57h was optimized with the desired analgesic and anti-inflammatory effect can be obtained by using propylene glycol and oleic acid co-solvents as a penetration enhancer. The patch was also found stable at 4˚C for a period of 6.44 months. Formulation F9 comprising of 10% PG and 3% OA was selected as an optimized formulation. The study demonstrates that the fabricated transdermal system of lornoxicam can deliver the drug through the skin in a controlled manner with desired analgesic and anti-inflammatory activity and can be considered as a suitable alternative of the oral route.

show abstract

Section: In Vitro Release Studymentioning

confidence: 99%

Section: Effect Of Gelling Agent Concentrationmentioning

confidence: 99%

Lornoxicam controlled release transdermal gel patch: Design, characterization and optimization using co-solvents as penetration enhancers

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Dexibuprofen, a NSAID has been reported to possess several biological activities such as anti-inflammatory, reported that the reservoir-type transdermal patch exhibiting controlled zero-order rate of release with suitable permeation rate was prepared. The findings of in vitro studies suggest effective delivery of dexibuprofen across skin 30 . Gels were prepared by dispersing the polymers in a mixture of water and glycerol with methyl paraben as the preservative and the varying amount of ibuprofen, being kept under magnetic stirring until the homogeneous dispersion was formed.…”

Section: Discussionmentioning

confidence: 95%

Formulation, Optimization and Characterization of Novel Modified Release Gel Formulation of Dexibuprofen Using Full Factorial Design

K¹,

Paramaguru²,

Kunchithapatham³

2020

Int J Pharma Bio Sci

View full text Add to dashboard Cite

The aim of the study is to prepare Dexibuprofen modified release gel for topical delivery to provide the drug release in a modified manner, decreasing the oral side effects of the drug and improving the stability. Dexibuprofen, an anti-inflammatory drug, was used to design Novel Modified Release Gel Formulation to avoid its first pass effect as well as to increase its bioavailability with decline in dosing rate and to reduce its adverse effects. Skin is the largest, most extensive and accessible organ for topical administration of drug on human body, compared to other organs for drug delivery. Skin is most important route of topical drug delivery system. Topical application of dosage forms offers several advantages of delivering the drug directly to the site of action and acts for an extended period of time. In this study, Dexibuprofen gel was prepared by aqueous process. Drug-Excipient compatibility study was performed for the selected excipients. A sum of 6 batches (Batch No. from F001 to F006) were arranged by means of different polymers for prototype development and these are evaluated for various parameters. Batch No. F006 was found to have better quality characteristics hence composition of this batch was taken forward for optimization. Formulation was optimized using full factorial design. Four independent factors were optimised with varying levels of Chitosan, Sepineo P 600, Lactic acid and stirrer rpm. JMP Software has given 19 trials with 3 centre points and three responses owing to quality characteristics of gel formulations namely pH, viscosity and spreadability. An Interaction between Independent factors and responses were studied. The stability studies were carried out for prepared gel formulation as per ICH guidelines. The prepared Dexibuprofen gel was evaluated for various parameters and it shows good spreadability of B.No. F006 and it is concluded that the formulation could be very promising for the topical use to relieve pain and reduce the inflammation.

show abstract

“…Other authors have also developed DXI transdermal patches for controlled DXI delivery [ 70 ]. In this sense, Ramzan Ali and colleagues developed a reservoir-type transdermal patch for a controlled delivery of DXI and evaluated its in vivo anti-inflammatory activity performing the carrageenan hind paw edema test in Albino Wistar rats.…”

Section: Novel Strategies For Dexibuprofen Drug Deliverymentioning

confidence: 99%

“…The formulation patch was compared with commercial DXI (previously dissolved tablets) in vivo, obtaining a plasmatic concentration 1.9 times higher with DXI patches than with the oral tablets [69]. Other authors have also developed DXI transdermal patches for controlled DXI delivery [70]. In this sense, Ramzan Ali and colleagues developed a reservoir-type transdermal patch for a controlled delivery of DXI and evaluated its in vivo anti-inflammatory activity performing the carrageenan hind paw edema test in Albino Wistar rats.…”

Section: Novel Strategies For Skin Dexibuprofen Deliverymentioning

confidence: 99%

Dexibuprofen Therapeutic Advances: Prodrugs and Nanotechnological Formulations

Gliszczyńska

2021

Pharmaceutics

View full text Add to dashboard Cite

S-(+) enantiomer of ibuprofen (IBU) dexibuprofen (DXI) is known to be more potent than its R-(−) form and exhibits many advantages over the racemic mixture of IBU such as lower toxicity, greater clinical efficacy, and lesser variability in therapeutic effects. Moreover, DXI potential has been recently advocated to reduce cancer development and prevent the development of neurodegenerative diseases in addition to its anti-inflammatory properties. During the last decade, many attempts have been made to design novel formulations of DXI aimed at increasing its therapeutic benefits and minimizing the adverse effects. Therefore, this article summarizes pharmacological information about DXI, its pharmacokinetics, safety, and therapeutic outcomes. Moreover, modified DXI drug delivery approaches are extensively discussed. Recent studies of DXI prodrugs and novel DXI nanoformulations are analyzed as well as reviewing their efficacy for ocular, skin, and oral applications.

show abstract

Design, Development, and Optimization of Dexibuprofen Microemulsion Based Transdermal Reservoir Patches for Controlled Drug Delivery

Cited by 20 publications

References 57 publications

Lornoxicam controlled release transdermal gel patch: Design, characterization and optimization using co-solvents as penetration enhancers

Lornoxicam controlled release transdermal gel patch: Design, characterization and optimization using co-solvents as penetration enhancers

Formulation, Optimization and Characterization of Novel Modified Release Gel Formulation of Dexibuprofen Using Full Factorial Design

Dexibuprofen Therapeutic Advances: Prodrugs and Nanotechnological Formulations

Contact Info

Product

Resources

About